Form 8-K TETRAPHASE PHARMACEUTICA For: Feb 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at Stifel; Path Forward Complicated, But Still There
February 14, 2018 6:28 AM ESTStifel lowered its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $6.00 (from $13.00) while maintaining a Buy rating following the Phase 3 IGNITE3 trial failure.
Analyst Stephen Willey commented, "The failure of the P3 IGNITE3 trial to demonstrate the non-inferiority (NI) of intravenously-administered eravacycline vs.... More
